Panacea Global Invited to Present Its Cancer Diagnostics Technology at the 2nd Global Life Sciences

Fri, 03 Oct 2014

TORONTO, ONTARIO--(Marketwired - Oct 3, 2014) - Panacea Global, Inc. ("Panacea") (PANG) a biotechnology company focused on the discovery, development and commercialization of diagnostic products for the management of cancer, today announced that Dr. Mahmood Moshiri, Chief Executive Officer will be presenting Panacea's novel cancer diagnostic technology at the 2nd Global Life Sciences Conference at the trading floor of the Warsaw Stock Exchange, Warsaw, Poland.

Warsaw, the financial capital of Central and Eastern Europe, is a major center of life science investment. On October 2nd, at the Global Life Sciences Conference, over 100 leading life science institutional investors, fund managers and analysts from Central and Eastern Europe will gather in Warsaw to discuss and assess new investment opportunities. They will have access there to Milestone Medical's management through a corporate presentation and small group meetings.

The organizers of this event are: WDM Capital, Wedbush Europe and the Filipex Enterprises. The partners of this event are: Warsaw Stock Exchange, Wedbush, Wierzbowski Eversheds and Crescendo Communications. For more information please visit: http://lscwarsaw.com.

About Panacea Global

Panacea Global is a biotechnology company focused on the development and commercialization of diagnostic products for the management of cancer. Panacea has developed an accurate, timely, cost effective and non-invasive early cancer detection test to increase the quality of life of cancer patients and ultimately saving lives. Panacea's test is based on the detection of the human aspartyl (asparaginyl) β-hydroxylase (HAAH), a novel biomarker expressed in malignant cancer cells in patients' blood samples. Panacea Global has the exclusive worldwide (excluding the USA) rights to HAAH-based cancer tests. More information about Panacea Global (PANG) is available at www.panaceaglobalinc.com.

Forward-looking statements

Certain information contained in this document may include "forward-looking information". Without limiting the foregoing, the information and any forward-looking information may include statements regarding projects, costs, objectives and future returns of the Company or hypotheses underlying these items. In this document, words such as "may", "would", "could", "will", "likely", "believe", "expect", "anticipate", "intend", "plan", "estimate" and similar words and the negative form thereof are used to identify forward-looking statements. Forward-looking statements should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, such future performance will be achieved. Forward-looking statements and information are based on information available at the time and/or the Company management's good-faith beliefs with respect to future events and are subject to known or unknown risks, uncertainties, assumptions and other unpredictable factors, many of which are beyond the Company's control. The Company does not intend, nor does it undertake, any obligation to update or revise any forward-looking information or statements contained in this document to reflect subsequent information, events or circumstances or otherwise, except as required by applicable laws.

Contact:

Panacea Global, Inc.

Company Contact:
Aras Azadian
aras@panaceaglobalinc.com
www.panaceaglobalinc.com

‹ Back to News

Comments

Write a comment